Puma Biotechnology Inc (PBYI)

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 1, 2026, the Compensation Committee of Puma’s Board...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Puma Biotechnology Reports First Quarter 2026 Financial Results

Raising 2026 Revenue and Net Income Guidance Based on Increased Demand for NERLYNX Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical...

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2026, the Compensation Committee of Puma’s Board...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May...

Form PRE 14A - Other preliminary proxy statements

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma’s Board...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December...

Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer...

Form 4 - Statement of changes in beneficial ownership of securities